Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq on DMSO and EPZ6438 treated CD34+ HSPCs

ABSTRACT: The overall goal is to understand how does the DNA methylation Canyon interactions in CD34+ HSPCs can be impacted by the inhibition of EZH2

ORGANISM(S): Homo sapiens

PROVIDER: GSE144131 | GEO | 2020/01/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

In Situ on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:The overall goal is to understand how does the DNA methylation Canyon interactions in CD34+ HSPCs can be impacted by the inhibition of EZH2

2020-01-24 | GSE144126 | GEO

H3K27me3 and H3K4me3 ChIP-seq on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:The overall goal is to understand how does the DNA methylation Canyon interactions in CD34+ HSPCs can be impacted by the inhibition of EZH2

2020-01-24 | GSE144124 | GEO

RNA-seq on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:RNA-seq on DMSO and EPZ6438 treated CD34+ HSPCs

| PRJNA602869 | ENA

In Situ on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:In Situ on DMSO and EPZ6438 treated CD34+ HSPCs

| PRJNA602860 | ENA

DARTseq identifies m6A targets in human CD34+ HSPCs

Project description:The goal of this study is to identify m6A targets in human CD34+ HSPCs with or without STM2457 treatment using DARTseq. Purified human CD34+ HSPC cells were transduced with APOBEC-YTH or empty vector control (MIG). 24hr post infection, CD34+ cells were treated with STM2457 at a concentration of 20µM for 2 days. GFP+ cells were sorted the next day. 3 replicates were performed.

2023-12-07 | GSE231861 | GEO

H3K27me3 and H3K4me3 ChIP-seq on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:H3K27me3 and H3K4me3 ChIP-seq on DMSO and EPZ6438 treated CD34+ HSPCs

| PRJNA602858 | ENA

Transcriptome of CBX7 and CBX8 overexpressing CD34+ HSPCs

Project description:Transcriptome of CBX7 and CBX8 overexpressing CD34+ HSPCs

| PRJEB22831 | ENA

RNA-seq of healthy CD34+ HSPCs after co-culture with myelodyplastic syndrome patient-derived mesenchymal stromal cells

Project description:Cytopenia in at least one of the hematopoietic lineages (RBCs, WBCs or platelets) is a hallmark feature of MDS, indicating the lack of ability to support HSPC proliferation and the retention of their multilineage potential in the bone marrow. Here, wel investigate MDS-MSCs (with and without 5-azacitidine pre-treatment) as feeder layers for healthy CD34+ HSPCs. We performed RNA sequencing of co-cultured CD34+ HSPCs to compare their transcriptomic signatures after exposure to treated vs untreated MDS-MSCs.

2019-09-30 | GSE119916 | GEO

Transcriptome profiling of quiescent and cytokine induced normal human haematopoietic CD34+ HSPCs, and AML blast cells

Project description:Control group is an essential part of the research design which provide a baseline by elimating variables, bias and other factors that skew the data. Human CD34+ cells are generally used as controls to study myeloid malignancies. This study determines whether fresh or short term cytokine induced CD34+ HSPCs can provide a more appropriate normal control (compared to AML blasts) for target discovery studies. We here determine that the GEP of CD34+ cells that do not undergo ex vivo expansion best match the GEP of minimally differentiated AML blasts and would serve as a better control to identify novel targets in the AML blast population.

2015-12-09 | E-MTAB-3328 | biostudies-arrayexpress

Bulk RNAseq of primary CD34+ HSPCs in Myeloproliferative neoplasms patients receiving tamoxifen

Project description:TAMARIN study is a Phase II, multicenter, single arm A’herns design clinical trial assessing tamoxifen’s safety and activity in reducing molecular markers of disease burden in MPN.The primary outcome (≥50% allele burden reduction at 24 weeks) was met by 3/37 patients; 5/37 additional patients showed ≥25% reductions. CD34+ HSPCs were collected from responders and non-respondersin the baseline line and 24W after tamoxifen treatment. RNAseq was performed to investigate the molecular signature about tamoxifen sensitivity and pharmacological mechanism of tamoxifen in MPN patients.

2023-10-02 | GSE172022 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data